The corporate name change to Cullinan Therapeutics reflects the company’s transformation as it pursues new indications for autoimmune diseases and continues to advance its clinical-stage oncology pipeline. The new corporate name represents both the expanded therapeutic focus area and Cullinan Therapeutics’ vision to evolve to a commercial-stage biotech company. The company’s common stock will continue to trade under its current ticker symbol “CGEM“. Along with the new name, the company will adopt a new logo and will change its corporate website from www.cullinanoncology.com to www.cullinantherapeutics.com.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Oncology initiated with an Outperform at William Blair
- Cullinan Management’s Capital Dilemma: Balancing Equity, Debt, and Partnerships to Avoid Dilution and Restrictions
- Cullinan Oncology announces departure of CFO Jeff Trigilio
- Cullinan Oncology expects cash to provide runway into 2H26
